Selective inactivation of butyrylcholinesterase with metal chelators suggests there is more than one metal binding site.
Cholinesterases exhibit functions apart from their esterase activity. We have demonstrated an aryl acylamidase and a zinc stimulated metallocarboxypeptidase activity in human serum butyrylcholinesterase. To establish the presence of zinc binding sites in the enzyme we examined the effect of metal chelators on its catalytic activities. The metal chelators 1,10-phenanthroline and N,N,N',N'-tetrakis (2-pyridyl methyl)ethylene diamine (TPEN) inhibited all the three catalytic activities in the enzyme. However, EDTA inhibited the peptidase activity exclusively without affecting the cholinesterase and aryl acylamidase activities. The catalytic activities were recovered upon removal of the chelator by Sephadex G-25 chromatography. Pre-treatment of the enzyme with any one of the three chelators resulted in the binding of the enzyme to a zinc-Sepharose column or to 65Zn2+. Histidine modification of the enzyme pretreated with chelators resulted in abolition of 65Zn2+ binding and zinc-Sepharose binding. Whereas the binding studies demonstrated removal of a metal from a Zn2+ binding site, attempts to remove the metal responsible for catalytic activity were unsuccessful. Atomic absorption spectroscopy indicated approximately 2.5 mol of zinc per mol of enzyme before treatment with EDTA and 1 mol zinc per mol enzyme after EDTA treatment. The results indicate that there are at least two metal binding sites on butyrycholinesterase. The presence of two HXXE...H sequences in butyrylcholinesterase supports these findings. Our studies implicate a zinc dependent metallocarboxypeptidase activity in the non-cholinergic functions of butyrylcholinesterase.
Bhanumathy
C D
CD
Department of Neurological Sciences, Christian Medical College and Hospital, Tamil Nadu, India.
Balasubramanian
A S
AS
D001665:Binding Sites; D002091:Butyrylcholinesterase / Q000378:metabolism*; D002384:Catalysis; D002614:Chelating Agents / Q000494:pharmacology*; D002800:Cholinesterase Inhibitors / Q000494:pharmacology*; D002850:Chromatography, Gel; D003545:Cysteine; D003911:Dextrans; D004492:Edetic Acid / Q000494:pharmacology; D005029:Ethylenediamines / Q000494:pharmacology*; D006639:Histidine; D006801:Humans; D008670:Metals; D010618:Phenanthrolines / Q000494:pharmacology*; D013054:Spectrophotometry, Atomic; D013997:Time Factors; D015032:Zinc
D002614:Chelating Agents; D002800:Cholinesterase Inhibitors; D003911:Dextrans; D005029:Ethylenediamines; D008670:Metals; D010618:Phenanthrolines; D006639:Histidine; C025614:sephadex; D004492:Edetic Acid; D002091:Butyrylcholinesterase; D015032:Zinc; D003545:Cysteine; C044387:N,N,N',N'-tetrakis(2-pyridylmethyl)ethylenediamine; C025205:1,10-phenanthroline